Resistance markers to sulfadoxine-pyrimethamine and amodiaquine in the context of seasonal malaria chemoprevention in Burkina Faso

In 2022, 8.3 million maria cases were reported in Burkina Faso. Since 2014, seasonal malaria chemoprevention (SMC), using antimalarial medicines sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ), has been implemented. However, there are no data on molecular resistance markers for these drugs. This study assessed resistance to SP and AQ by examining specific molecular markers in blood samples from the Boussé district before and after SMC in 2022. This poster was presented at the 72nd annual meeting of the American Society of Tropical Medicine and Hygiene.

Click here to download

Country: Burkina Faso